Skip to main content

Table 4 Impact of NMD on COVID-19

From: A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases

  Low COVID-19 severity (n = 48)
No. (%)
Moderate COVID-19 severity (n = 23)
No. (%)
High COVID-19 severity (n = 12)
No. (%)
p-value
Type of disease     0.095
 Myopathy 16 (59.3) 8 (29.6) 3 (11.1)  
 Neuropathy 12 (52.2) 10 (43.5) 1 (4.3)  
 Myasthenia 20 (60.6) 5 (15.2) 8 (24.2)  
Origin of the disease     0.199
 Acquired 24 (55.8) 10 (23.3) 9 (20.9)  
 Genetic 23 (59.0) 13 (33.3) 3 (7.7)  
Severity of neuromuscular diseaseƗ     0.007*
 Low 21 (72.4) 6 (20.7) 2 (6.9)  
 Moderate 22 (61.1) 8 (22.2) 6 (16.7)  
 High 3 (18.8) 9 (56.2) 4 (25.0)  
Mobility     0.015*
 Walk 40 (70.2) 12 (21.1) 5 (8.8)  
 Walk with help 5 (41.7) 4 (33.3) 3 (25.0)  
 Wheelchair 3 (25.0) 6 (50.0) 3 (25.0)  
Gender     0.031*
 Men 14 (41.2) 14 (41.2) 6 (17.6)  
 Women 34 (69.4) 9 (18.4) 6 (12.2)  
Age > 65 yrs old 9 (47.4) 9 (47.4) 1 (5.3) 0.070
Respiratory failure 12 (42.9) 10 (35.7) 6 (21.4) 0.079
Heart failure 8 (50.0) 6 (37.5) 2 (12.5) 0.617
Obesity 2 (25.0) 4 (50.0) 2 (25.0) 0.097
Hypertension 1 (9.1) 7 (63.6) 3 (27.3) 0.001*
Diabetes 1 (10.0) 4 (40.0) 5 (50.0) 0.001*
Corticosteroids‡,§ 6 (46.2) 4 (30.8) 3 (23.1) 0.670
Immunosuppressants other than corticosteroids‡,§ 8 (50.0) 4 (25.0) 4 (25.0) 0.764
  1. n number of cases, No. (%) number of cases (% of cases)
  2. ƗAccording to the physician
  3. Prior to COVID-19
  4. §Statistical analysis have been performed only on populations with acquired diseases
  5. *p < 0.05 was statistically significant